Last reviewed · How we verify
nadroparin calcium-warfarin sequential anticoagulation
A sequential anticoagulation regimen combining nadroparin calcium (low-molecular-weight heparin) followed by warfarin to prevent thromboembolism.
A sequential anticoagulation regimen combining nadroparin calcium (low-molecular-weight heparin) followed by warfarin to prevent thromboembolism. Used for Venous thromboembolism prevention and treatment, Atrial fibrillation with thromboembolism risk.
At a glance
| Generic name | nadroparin calcium-warfarin sequential anticoagulation |
|---|---|
| Also known as | anticoagulation |
| Sponsor | Qilu Hospital of Shandong University |
| Drug class | Anticoagulant combination (LMWH + vitamin K antagonist) |
| Target | Factor Xa, thrombin (nadroparin); vitamin K-dependent clotting factors II, VII, IX, X (warfarin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nadroparin calcium is a low-molecular-weight heparin that inhibits Factor Xa and thrombin, providing rapid anticoagulation. Warfarin is a vitamin K antagonist that inhibits synthesis of vitamin K-dependent clotting factors (II, VII, IX, X), providing sustained anticoagulation. The sequential approach uses nadroparin for initial rapid anticoagulation, then transitions to warfarin for long-term maintenance therapy.
Approved indications
- Venous thromboembolism prevention and treatment
- Atrial fibrillation with thromboembolism risk
Common side effects
- Bleeding
- Thrombocytopenia
- Heparin-induced thrombocytopenia (HIT)
- Skin necrosis
Key clinical trials
- Safety of Anticoagulant Therapy After Endoscopic Treatment (PHASE4)
- Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: